JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

JNJ

192.2

-0.47%↓

ABT

127.06

-1.1%↓

MDT

93.96

-2.69%↓

VEEV

289

-0.19%↓

146.19

+0.72%↑

Начало・Списък с акции・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Отворен

4.4 0.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.32

Максимум

4.44

Ключови измерители
By Trading Economics
Приходи	27M 2.5M
Продажби	9M 11M
Марж на печалбата	23.494
Служители	44
EBITDA	27M 2.6M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	233M 872M
Предишно отваряне	3.94
Предишно затваряне	4.4

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

3.255 / 3.365 Подкрепа & съпротива

Arbutus Biopharma Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.10.2025 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22.10.2025 г., 22:13 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22.10.2025 г., 21:20 ч. UTC

Печалби

Correction to IBM 3Q Sales Jump Article

22.10.2025 г., 20:57 ч. UTC

Печалби

SAP Posts Higher 3Q Revenue, Operating Profit

22.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22.10.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22.10.2025 г., 23:38 ч. UTC

Пазарно говорене

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22.10.2025 г., 23:15 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22.10.2025 г., 22:28 ч. UTC

Пазарно говорене

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22.10.2025 г., 22:02 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22.10.2025 г., 21:59 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22.10.2025 г., 21:58 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22.10.2025 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22.10.2025 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22.10.2025 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22.10.2025 г., 21:47 ч. UTC

Печалби

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22.10.2025 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22.10.2025 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22.10.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22.10.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22.10.2025 г., 21:28 ч. UTC

Пазарно говорене

Печалби

Correction to Alcoa Tariff Market Talk

22.10.2025 г., 21:25 ч. UTC

Печалби

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22.10.2025 г., 21:17 ч. UTC

Печалби

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22.10.2025 г., 21:09 ч. UTC

Пазарно говорене

Печалби

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22.10.2025 г., 21:00 ч. UTC

Пазарно говорене

ESG Roundup: Market Talk

22.10.2025 г., 20:59 ч. UTC

Печалби

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22.10.2025 г., 20:51 ч. UTC

Печалби

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.10.2025 г., 20:44 ч. UTC

Печалби

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Сравнение с други в отрасъла

Ценова промяна

Arbutus Biopharma Corp Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Arbutus Biopharma Corp през последните 3 месеца.

Техническа оценка

By Trading Central

3.255 / 3.365Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.